Does Herpes Medication Prevent Transmission?

Daily antiviral medication cuts the risk of passing genital herpes to a partner roughly in half, but it does not eliminate that risk entirely. The best-studied regimen, daily valacyclovir, was shown in a large trial to reduce overall HSV-2 acquisition by about 48% in couples where one partner was infected and the other was not. That partial protection makes antivirals a genuinely useful tool, but the gap between “reduces” and “prevents” matters a great deal for real-world decisions about sex, disclosure, and combination strategies.

What the Largest Trial Actually Found

The most influential study on this question enrolled nearly 1,500 couples in which one partner had genital herpes and the other did not. The infected partner took either 500 mg of valacyclovir daily or a placebo for eight months. Among partners of people taking valacyclovir, about 1.9% acquired HSV-2 over the study period, compared with 3.6% in the placebo group. When the researchers looked only at infections that caused noticeable symptoms, just 4 partners in the valacyclovir group developed symptomatic herpes compared with 16 in the placebo group, a 75% reduction in clinical disease.¹

Those numbers deserve a closer look because they are often simplified in ways that mislead. The “48% reduction” refers to all HSV-2 acquisition, including infections that the newly infected partner might never have noticed without blood testing. The “75% reduction” applies to infections that actually caused visible outbreaks. Both numbers are real, but the one that matters most to you depends on whether you define transmission as any detectable infection or only an infection that causes symptoms. Most people care about the latter, and the protection there looks stronger.

Still, even the more encouraging figure means some partners will acquire herpes despite daily medication. The trial was conducted under conditions that included counseling on safer sex practices and condom use, so the medication was not working alone. Suppressive therapy reduces risk; it does not create a force field.

How Antivirals Reduce the Risk

Herpes spreads primarily through viral shedding, the release of virus particles from skin or mucous membranes. Shedding happens during visible outbreaks but also on days when the skin looks completely normal. This “subclinical” shedding is actually responsible for most transmissions, because people tend to avoid sex during visible sores but have no way of knowing when they are shedding without symptoms.

Daily valacyclovir dramatically cuts shedding. In a study of people newly diagnosed with genital herpes, shedding occurred on about 13.5% of days while taking a placebo versus 2.9% of days while on valacyclovir, a 78% reduction. Subclinical shedding specifically dropped by the same margin, from about 11% of days to 2.4%.² Less virus on the skin on fewer days means fewer opportunities for the virus to jump to a partner. The medication does not eliminate shedding entirely, which is why transmission can still occur, but it shrinks the window considerably.

This shedding reduction also explains why suppressive therapy is more effective at preventing transmission than episodic treatment, where you take medication only when an outbreak appears. In a head-to-head comparison, people on daily suppressive valacyclovir experienced far fewer outbreaks and fewer days with active lesions than those who only took the drug during flare-ups.³ Episodic treatment helps you heal faster when you have a sore, but it does nothing about the invisible shedding on all those symptom-free days. If your goal is to protect a partner, daily suppressive therapy is the strategy with evidence behind it.

Combining Medication with Condoms

Neither antivirals nor condoms alone offer full protection, and the data from the landmark valacyclovir trial reflects a population that was advised to use both. Condoms on their own reduce herpes transmission by a meaningful amount, though estimates vary depending on the study, and their protection is partial because herpes can shed from skin that a condom does not cover. Adding daily valacyclovir on top of consistent condom use creates a layered defense. The combination is the closest thing the evidence supports to a high-confidence risk-reduction strategy, but the honest framing is that it lowers risk substantially, not that it guarantees safety.

Some couples in long-term discordant relationships decide the residual risk is acceptable with medication and condoms. Others choose to use one but not the other, and some forgo both. The data can inform these decisions, but it cannot make them for you. What the evidence does make clear is that daily antivirals and condom use together do better than either one in isolation.⁴

Why Transmission Still Happens Despite Medication

Several factors explain the gap between reduced shedding and complete prevention. First, even with a 78% reduction in shedding days, shedding still happens on roughly 3% of days. Over months and years of sexual contact, those days accumulate. Second, the amount of virus shed during a breakthrough episode may sometimes be enough to infect a partner, even if the overall viral load is lower than it would be without treatment. Third, adherence matters. The clinical trial data reflects people who were monitored, counseled, and had study drug supplied reliably. In real life, missed doses, gaps in refills, and inconsistent use erode the benefit.

There is also biological variability that medication cannot control. Some people shed virus more frequently than others regardless of treatment, and a partner’s individual susceptibility plays a role. Minor skin breaks, hormonal fluctuations, and immune status on any given day all affect whether an exposure turns into an infection. Medication tilts the odds, but bodies are not deterministic machines.

A Different Picture for People Living with HIV

The reassuring data from the valacyclovir transmission trial involved people with otherwise healthy immune systems. For people co-infected with both HSV-2 and HIV, the story is notably less encouraging. A systematic review of studies in HIV-positive populations found that suppressive acyclovir reduced how often HSV was detected on genital swabs but did not translate into a meaningful reduction in actual HSV-2 transmission. In the one trial that directly measured transmission between partners, the rate was about 9% in the acyclovir group versus 6% on placebo, a difference that was not statistically significant and, if anything, trended in the wrong direction.⁵

A large randomized trial of African couples co-infected with HIV-1 and HSV-2 confirmed this finding. Daily acyclovir did not decrease the risk of HSV-2 transmission to susceptible partners.⁶ A separate large trial also found that suppressive acyclovir in people with both infections reduced HSV-2 genital ulcers by 73% and lowered HIV plasma levels modestly, but it did not reduce the rate of HIV transmission to uninfected partners.⁷

The reasons for this disconnect likely involve the compromised immune environment. HIV weakens the local immune defenses that normally help contain HSV replication, and the doses of acyclovir used in these trials may not have been potent enough to overcome that impairment. For people living with HIV, the primary tool for reducing transmission of both viruses is effective antiretroviral therapy, not HSV-specific suppression alone. The lesson here is that the roughly 48% reduction figure from the valacyclovir trial should not be assumed to apply universally across all populations.⁸

Pregnancy and Protecting Newborns

Herpes transmission takes on a different urgency during pregnancy, because neonatal herpes, though rare, can be devastating. The concern centers on active viral shedding at the time of delivery: if a mother has an outbreak or is shedding virus when the baby passes through the birth canal, the infant faces a risk of serious infection. The standard approach is to start suppressive antiviral therapy in the third trimester for women with a history of genital herpes.

A Cochrane systematic review pooling several trials found this strategy to be effective on multiple fronts. Women who received antiviral prophylaxis in late pregnancy were about 72% less likely to have a herpes recurrence at delivery, about 70% less likely to need a cesarean delivery for active herpes, and about 86% less likely to have detectable HSV at the time of delivery.⁹ These are substantial reductions, and the safety profile of acyclovir and valacyclovir in pregnancy is well established, which is why this approach is widely recommended by obstetric guidelines.

That said, an earlier cost-effectiveness analysis highlighted that because neonatal herpes is already rare, the number of women who need to take prophylaxis to prevent a single neonatal infection is high, roughly 1,800 in one model. The same analysis found that for every 7 or 8 women treated, one maternal outbreak at delivery was prevented.¹⁰ The math favors treatment because the cost of prophylaxis is low and the consequences of neonatal herpes are severe, but it illustrates that even in this context, antivirals are reducing an already uncommon event rather than heading off a common one.

Drug Resistance and Immunocompromised Patients

Acyclovir and its relatives work by interfering with a specific viral enzyme that the virus uses to copy its DNA. For most people, the virus does not easily develop resistance to these drugs, and long-term suppressive therapy remains effective for years. However, in people with significantly weakened immune systems, resistant strains can and do emerge.

Case reports describe patients with primary immunodeficiency disorders who develop herpes lesions that do not respond to acyclovir. One reported case involved a young child with DOCK8 deficiency, a rare genetic immune condition, who developed a cutaneous herpes lesion despite acyclovir prophylaxis. The infection only resolved after treatment with foscarnet, a different antiviral that works through a separate mechanism.¹¹ Transplant recipients on immunosuppressive drugs and people with advanced HIV are also at elevated risk for acyclovir-resistant herpes.

For the general population taking suppressive therapy with a healthy immune system, clinically significant resistance is uncommon. But the possibility matters for two reasons. First, if you are immunocompromised and notice that outbreaks are not responding to your usual medication, that is worth flagging with your doctor rather than assuming the drug just is not working well enough. Second, it underscores why developing new antivirals with different mechanisms is important for the long-term management of herpes.

Newer Drugs That May Do Better

The current mainstays, acyclovir, valacyclovir, and famciclovir, all belong to the same drug class and target the same viral enzyme. Pritelivir is a newer antiviral that works through an entirely different mechanism, blocking a different step in viral DNA replication. In a randomized trial comparing pritelivir head-to-head with valacyclovir in people with frequent herpes recurrences, pritelivir reduced genital shedding to 2.4% of days compared with 5.3% on valacyclovir. Visible genital lesions were present on 1.9% of days with pritelivir versus 3.9% with valacyclovir.¹²

Those are roughly halved shedding rates compared to the current standard, which is encouraging. Whether that translates into a proportional reduction in actual partner-to-partner transmission has not yet been tested in a large outcomes trial, and shedding is only a surrogate marker. But the direction is promising. Pritelivir has been granted expanded access in the United States for immunocompromised patients with acyclovir-resistant herpes, and broader approval could follow if larger trials confirm its benefits.

There is also early-stage work on topical microbicides. Tenofovir, a drug better known for HIV prevention, has shown activity against HSV-2 in laboratory studies and in clinical trials of a vaginal gel. The catch is that it needs to reach high local concentrations to suppress herpes, which means topical delivery rather than the oral formulation used for HIV.¹³ A topical product that could independently reduce herpes transmission at the site of contact would add another layer to the prevention toolkit, though no such product is currently approved for this purpose.

What Adherence Looks Like in Practice

Clinical trials involve regular check-ins, free medication, and motivated participants. Real-world adherence to daily suppressive therapy is messier. People forget doses, run out of prescriptions, stop taking the medication when they have been outbreak-free for a while, or discontinue because of cost or the psychological burden of taking a daily pill for a condition that feels manageable. Each missed dose is a window in which viral shedding can rebound, potentially without the person noticing.

Suppressive antiviral therapy has been shown to reduce both symptomatic and asymptomatic viral shedding, and it is the asymptomatic shedding that drives most transmission between partners.¹⁴ This means the benefit of medication depends on consistent, daily use. Taking it “most days” is better than not taking it, but the clinical evidence for a roughly 48% transmission reduction assumes near-daily adherence. If you are taking it primarily to protect a partner, consistency is where a lot of the real-world effectiveness lives or dies.

Pharmacy data and patient surveys consistently show that adherence to any daily medication for a chronic condition drifts downward over time. With herpes specifically, people often feel best about adherence when they are in a newer relationship and motivated by the desire to protect someone, and less diligent years later when the condition feels routine. If you are relying on medication as part of your risk-reduction strategy, being honest with yourself about how reliably you actually take it matters more than the published efficacy numbers.

The Stigma Gap Between Data and Feeling

Herpes medication sits at the intersection of biology and social anxiety in a way that few other drugs do. For many people, the question “does medication prevent transmission” is really a question about whether they can have a normal sex life, disclose their status with confidence, and feel less defined by a diagnosis. The data gives a partial but genuinely useful answer: daily antivirals cut transmission risk substantially, and combining them with condoms pushes the residual risk quite low. For most discordant couples using both, the per-year risk of a partner acquiring herpes is in the low single digits.

What the data cannot do is eliminate uncertainty, and uncertainty is what drives a lot of the distress around herpes. The psychological weight of knowing you could still transmit the virus, even while doing everything right, is real. Some people find that understanding the actual numbers helps calibrate their anxiety. Knowing that the annual risk with medication and condoms is somewhere around 1-2% reframes the situation from “I am dangerous” to “there is a small residual risk that my partner and I have decided to accept.” Others find that no number is small enough to remove the worry entirely, and that is a legitimate emotional response, not a failure to understand the science.

It is also worth noting that the cultural perception of herpes as uniquely terrible has always been out of proportion to its medical reality. Most people with genital herpes have mild or infrequent symptoms, many never know they have it, and the virus poses no serious health threat to adults with normal immune function. The availability of effective suppressive medication adds another reason to approach the diagnosis as a manageable condition rather than a catastrophe. The medication is not perfect, but perfection is a standard that few medical interventions for any sexually transmitted infection actually meet.